Verona Pharma PLC
NASDAQ:VRNA

Watchlist Manager
Verona Pharma PLC Logo
Verona Pharma PLC
NASDAQ:VRNA
Watchlist
Price: 86 USD Market Closed
Market Cap: 7.4B USD

Operating Margin
Verona Pharma PLC

-25.3%
Current
-4 896%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-25.3%
=
Operating Profit
-56m
/
Revenue
221.7m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
UK
Verona Pharma PLC
NASDAQ:VRNA
7.4B USD
-25%
US
Eli Lilly and Co
NYSE:LLY
971.9B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
509.1B USD
27%
CH
Roche Holding AG
SIX:ROG
252.3B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP
24%
CH
Novartis AG
SIX:NOVN
202.4B CHF
33%
US
Merck & Co Inc
NYSE:MRK
249.5B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
147B USD
29%
No Stocks Found

Verona Pharma PLC
Glance View

Market Cap
7.4B USD
Industry
Pharmaceuticals

Verona Pharma PLC, an ambitious player in the biopharmaceutical arena, is woven into the intricate tapestry of the healthcare industry, focusing its energies on respiratory ailments. Born within the thriving biopharma sector in London, this company has targeted chronic obstructive pulmonary disease (COPD) with its novel therapies, driven by the urgent need to alleviate this global burden. The company's flagship product, ensifentrine, serves as a dual inhibitor of the enzymes phosphodiesterase 3 and 4, aiming to enhance lung function and ease the constriction challenges faced by patients. Through strategic clinical trials and robust scientific inquiry, Verona Pharma seeks not only to innovate in treatment but also to deliver tangible hope for those grappling with chronic respiratory conditions. Verona Pharma's business model is anchored in advancing its drug development pipeline, propelled by a blend of scientific rigor and strategic partnerships. It capitalizes on patent protection and licensing agreements to secure its financial footing, investing heavily in research to drive value creation. The company earns its revenue predominantly from collaborative agreements with larger pharmaceutical entities, milestone payments, and potential royalties upon successful commercialization of its therapies. Through aligning with other industry giants, Verona Pharma not only financially fortifies its pursuits but also accelerates the dissemination of its therapeutic innovations, ensuring that their beneficial impacts reach as many patients as possible. This harmonized approach with partners places Verona Pharma on a trajectory not just of financial growth but also of achieving its underlying mission – transforming the landscape of respiratory disease management.

VRNA Intrinsic Value
62.44 USD
Overvaluation 27%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-25.3%
=
Operating Profit
-56m
/
Revenue
221.7m
What is the Operating Margin of Verona Pharma PLC?

Based on Verona Pharma PLC's most recent financial statements, the company has Operating Margin of -25.3%.

Back to Top